Access count of this item: 113

Files in This Item:
File Description SizeFormat 
16_0531.pdf9.27 MBAdobe PDFView/Open
Title: Progestational steroid(gestonorone caproate)による前立腺肥大症の治療
Other Titles: Treatment of prostatic hypertrophy with progestational steroid (gestonorone caproate)
Authors: 田中, 広見  KAKEN_name
福重, 満  KAKEN_name
白石, 恒雄  KAKEN_name
Author's alias: Tanaka, Hiromi
Fukushige, Mitsuru
Shiraishi, Tsuneo
Keywords: Aged
Animals
Caproates/pharmacology/therapeutic use
Estrogens/pharmacology
Humans
Injections, Intramuscular
Male
Middle Aged
Pregnanes/pharmacology/therapeutic use
Prostate/drug effects/pathology
Prostatic Hyperplasia/drug therapy
Rats
Testis/drug effects/pathology
Issue Date: Sep-1970
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 16
Issue: 9
Start page: 531
End page: 550
Abstract: 1) SH 582 (gestonorone caproate) was used in 11 cases of prostatic hypertrophy (7 in the first or second stage, and 4 in the third stage). a) Subjective symptoms were improved in 6 cases and unchanged in 1 case with hypertrophy of the first or second stage. b) Residual urine volume was reduced in 6 cases and unchanged in 1 case with hypertrophy of the first or second stage. None of the cases in the third stage showed any favorable change in residual urine volume. c) Strength of urinary flow was improved in 5 and unchanged in 2 cases with hypertrophy of the first or second stage. None of the cases in the third stage showed any improvement in strength of urinary flow. d) SH 582 is to be used for prostatic hypertrophy of the first or second stage. We think that it must be administered at weekly doses of 400 mg for more than 3 months. e) There were no side-effects at all. 2) SH 582, when administered to rats, did not produce such an atrophic change of the prostate and testis as is observed after estrogen administration.
URI: http://hdl.handle.net/2433/121159
PubMed ID: 4097365
Appears in Collections:Vol.16 No.9

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.